Registr.No. 86681079 CoC Amsterdam

Stichting Alivia International Foundation

Amsterdam, the Netherlands

ANNUAL REPORT

for the period ended 31 December 2023

Registr.No. 86681079 CoC Amsterdam

Balance Sheet as at 31 December 2023

(Before appropriation of results and expressed in euros)

	Notes	31 December 2023	31 December 2022
FIXED ASSETS			
Financial fixed assets			
Long-term loans Securities	1 2	410.000 389.995	150.000
TOTAL FIXED ASSETS		799.995	150.000
CURRENT ASSETS			
Securities	2	304.333	-
Cash	3	185.424	589.288
TOTAL CURRENT ASSETS		489.757	589.288
TOTAL ASSETS		1.289.752	739.288
OWN FUNDS			
Other reserves		739.288	-
Result for the period		550.464	739.288
		1.289.752	739.288

Registr.No. 86681079 CoC Amsterdam

Profit and Loss for the period 01.01.2023 - 31.12.2023

(Expressed in euros)

	Notes	01/01/2023 - 31/12/2023	10/06/2022 - 31/12/2022
INCOME From donations	4	590.710	750.000
OPERATING EXPENSES			
General and administrative expenses	5	65.698	10.688
TOTAL OPERATING EXPENSES		65.698	10.688
FINANCIAL INCOME / (EXPENSES) Interest income and similar income		25.452	-
Interest expenses and similar charges			(24)
TOTAL FINANCIAL INCOME / (EXPENSES)		25.452	(24)
NET RESULT		550.464	739.288

Registr.No. 86681079 CoC Amsterdam

Notes to the Financial statements 2023

General

Stichting Alivia International Foundation ("the Foundation") was incorporated on 10 June 2022 under the laws of the Netherlands. The Foundation has its statutory seat in Amsterdam and its business seat at Kabelweg 57, 1014 BA Amsterdam.

The purpose of the Foundation is to fight cancer. The Foundation acts to ensure equal access to the best cancer care for everyone, everywhere; defends the dignity of cancer patients and provide tools that enable them to make informed health decisions; undertakes its actions across borders.

The Foundation doesn't aim to make a profit.

Foundation's assets stand at sufficient level to compensate / cover ordinary Foundation's expenditures. The Foundation's resources consist of contributions by Alivia National Organizations (ANOs) — non-profit organizations registered in another countries and operating under the Alivia brand; gifts, donations, grants and bequests; interest and financial gains; third party contributions; subsidies; income from investment; benefits arising from any other source and other income.

These financial statements cover the period from 1 January 2023 till 31 December 2023.

Summary of principal accounting policies

The financial statements have been prepared in accordance with the provisions of EU Directives as implemented in Part 9, Book 2 of the Netherlands Civil Code.

The Annual report has been prepared on a going concern basis.

These financial statements are presented in euros (EUR), which is the Foundation's functional currency. Transactions in foreign currency during the period in review are included in the annual accounts at the settlement rate.

Purchased bonds are measured at amortised cost.

Unless mentioned otherwise all other assets and liabilities are stated at historical (acquisition) prices.

Receivables, payables and liabilities in foreign currency are converted at the rate of the balance sheet date, except in so far as the exchange rate risk is covered. In those cases, valuation takes place at the agreed forward rates.

Exchange rate differences resulting from this conversion are included in the profit and loss account. The exchange rate used as at December 31, 2023 is:

PLN/EUR = 4,3395

The "accrual concept" has been applied; meaning that items are accounted for in the period in which they were earned/incurred, regardless of the moment of receipt or payment.

The Foundation is not liable to pay corporate tax.

Registr.No. 86681079 CoC Amsterdam

Notes to the Financial statements 2023

1. Long-term loans

Three loan agreements were made between the Foundation and Alivia Fundacion Oncologica (Spain) for the total amount of EUR 410.000:

Date	Loan amount	Maturity date
21.10.2022	100.000,00	31.12.2026
14.12.2022	50.000,00	31.12.2027
25.01.2023	260.000,00	31.12.2027

The interest rate for all loans is settled to 0% per year.

2. Securities

On July 24th, 2023 the Foundation bought 16.420 bonds with a nominal value of 100 PLN each. These bonds have a maturity date of July 24th, 2027. The annual interest rate is 7% for the first interest period.

On August 2nd, 2023 the Foundation purchased Netherlands government bonds in the amount of EUR 300.000. These bonds have a maturity date of July 15th 2024 and bear an interest rate of 3,34%.

3. Cash

The Foundation maintains its bank account, denominated in EUR, USD and PLN, with Alior Bank (Poland). The bank balances are available on demand.

4. Income from donations

In 2023 the Foundation received EUR 590.710 according to the Donation agreement made and entered into as of January 4th, 2023 by and between Alivia – Fundacja Onkologiczna (Poland) and Stichting Alivia International Foundation.

5. General and administrative expenses

General and administrative expenses in the amount to EUR 65.698 are comprised of administration expenses, consultancy fees and bank charges for the period from 1 January 2023 till 31 December 2023.

Registr.No. 86681079 CoC Amsterdam

Notes to the Financial statements 2023

Staff

During the reporting period, the Foundation had no employee.

Board members

The Foundation had one board member and three supervisory board members during the reporting period. The board members did not receive any remuneration for the duties of the board members.

Place: Warsaw / Amsterdam

Agata Polinska

Date: June 30th

2024

DocuSigned by:

Ms. Agata Izabela Polińska

Board member

DocuSigned by:

Mr. Robert Bron

Supervisory board member

DocuSigned by:

Barbara Dobrowolska

Ms. Barbara Anna Dobrowolska

Supervisory board member

DocuSigned by:

Pawel Urawski —B105B80534A3488.... Man Dawel Tood on Ur

Mr. Pawel Teodor Urawski Supervisory board member

Registr.No. 86681079 CoC Amsterdam

Table of Contents

	<u>Page</u>
Financial Statements	
1. Balance Sheet as at 31 December 2023	1
2. Profit and Loss account for the period 01/01/2023 – 31/12/2023	2
3. Notes to the financial statements 2023	3 - 5